Understanding the WISeR Model: Implications for Medicare Services

In January 2026, the Centers for Medicare & Medicaid Services (CMS) launched the Wasteful and Inappropriate Service Reduction (WISeR) model. This initiative introduced prior authorization for specific services under traditional Medicare in selected states, aiming to minimize unnecessary medical care through this mechanism and artificial intelligence. States currently participating in the trial include Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington, collaborating with various technology vendors like Cohere Health and Innovaccer.

The WISeR program has sparked debate primarily due to the potential effects of prior authorization on access to necessary healthcare services. Neil Patil from Georgetown’s Center on Health Insurance Reform explains that while the model aims to reduce redundant treatments, its reliance on AI could lead to higher denial rates and exacerbate healthcare disparities.

Legislative Challenge to WISeR

Recently, a group of Democratic lawmakers responded by introducing a resolution under the Congressional Review Act (CRA) to repeal WISeR. This push follows a Government Accountability Office statement identifying new prior authorization mandates under WISeR that warrant Congressional scrutiny. The CRA allows Congress to review and potentially nullify federal agency regulations.

As part of these efforts, legislators like Sen. Ron Wyden and Rep. Suzan DelBene are advocating for a vote within a 60-day window that began on May 12. If successful in both legislative chambers, the resolution would proceed to the President’s desk. However, the likelihood of repeal faces uncertainty, especially given the model's origins during the Trump administration and the prospect of a presidential veto if originating legislation finds substantial support.

Industry Observations and Concerns

Beyond policy debates, industry observers question the long-term feasibility of the WISeR approach. Michael Abrams from Numerof & Associates points out that while prior authorization is a new introduction for traditional Medicare, its use in Medicare Advantage (MA) already faces criticism for slowing access and adding administrative challenges. Moreover, financial incentives in WISeR for reducing spending might result in higher denial rates—echoing past issues in MA programs where numerous denials are overturned.

Organizations like AARP also express concerns, emphasizing the balance needed between curbing fraud and ensuring beneficiaries receive essential care. Consistent with these apprehensions, anecdotal evidence suggests the WISeR trial faces technical difficulties, with authorization rates notably lower than those in Medicare Advantage, as reported by the Georgetown Medicare Policy Initiative.

The future of the WISeR initiative thus remains in flux as stakeholders continue to navigate its regulatory and operational complexities.